Marianne de Backer - 22 Feb 2026 Form 4 Insider Report for Vir Biotechnology, Inc. (VIR)

Role
Chief Executive Officer, Director
Signature
/s/ Vanina de Verneuil, Attorney-In-Fact
Issuer symbol
VIR
Transactions as of
22 Feb 2026
Net transactions value
-$141,894
Form type
4
Filing time
24 Feb 2026, 19:09:28 UTC
Previous filing
04 Apr 2025
Next filing
26 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
De Backer Marianne Chief Executive Officer, Director C/O VIR BIOTECHNOLOGY, INC., 1800 OWENS STREET, SUITE 900, SAN FRANCISCO /s/ Vanina de Verneuil, Attorney-In-Fact 24 Feb 2026 0001797819

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VIR Common Stock Award $0 +285,000 +37% $0.000000 1,054,505 22 Feb 2026 Direct F1
transaction VIR Common Stock Sale $141,894 -19,039 -1.8% $7.45 1,035,466 23 Feb 2026 Direct F2
holding VIR Common Stock 53,118 22 Feb 2026 See Footnote F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction VIR Stock Option (Right to Buy) Award $0 +570,000 $0.000000 570,000 22 Feb 2026 Common Stock 570,000 $7.56 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan.
F2 Represents an automatic and mandatory sale of shares under a Rule 10b5-1 arrangement to satisfy the Issuer's tax withholding obligations in connection with the vesting of RSUs. The sale does not represent a discretionary trade by the Reporting Person.
F3 The shares are held in the name of the Ureel-De Backer Family Trust, of which the Reporting Person and her spouse are Trustees.
F4 25% of the shares subject to the stock option will vest and become exercisable on February 22, 2027, and the remaining shares will vest in 36 equal monthly installments thereafter.